Access to cancer drugs in Canada: Looking beyond coverage decisions

Roger Chafe, Anthony Culyer, Mark Dobrow, Peter C. Coyte, Carol Sawka, Susan O'Reilly, Kara Laing, Maureen Trudeau, Sharon Smith, Jeffrey S Hoch, Steve Morgan, Stuart Peacock, Rick Abbott, Terrence Sullivan

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Objective: To examine variation in patients' access to a set of cancer drugs through publicly funded provincial drug programs. Data Sources/Study Design: We surveyed provincial drug program managers about their highest-expenditure intravenous and oral cancer drugs. We then investigated whether the same cancer drugs account for the highest expenditures across the provincial programs. We also compared the rates at which these drugs are accessed through these programs. Principal Findings: While there is moderate consistency in the selection of cancer drugs that account for the highest provincial expenditures, considerable differences were found in the rates at which some drugs are accessed across provincial programs. Conclusions: The study demonstrates the existence of interprovincial variation in publicly funded access to cancer drugs even after these drugs have been approved for public coverage.

Original languageEnglish (US)
Pages (from-to)27-35
Number of pages9
JournalHealthcare Policy
Volume6
Issue number3
StatePublished - Jan 2011
Externally publishedYes

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Access to cancer drugs in Canada: Looking beyond coverage decisions'. Together they form a unique fingerprint.

  • Cite this

    Chafe, R., Culyer, A., Dobrow, M., Coyte, P. C., Sawka, C., O'Reilly, S., Laing, K., Trudeau, M., Smith, S., Hoch, J. S., Morgan, S., Peacock, S., Abbott, R., & Sullivan, T. (2011). Access to cancer drugs in Canada: Looking beyond coverage decisions. Healthcare Policy, 6(3), 27-35.